Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands

Vaccine

Volumn 27, Issue 35, 2009, Pages 4776-4783

  Rogoza, R M ^a   Westra, T A ^b,c   Ferko, N ^a   Tamminga, J J ^d   Drummond, M F ^e,f   Daemen, T ^b   Wilschut, J C ^b   Postma, M J ^b,c  

^a Health Economics and Outcomes Research   (Canada)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d GLAXOSMITHKLINE   (Netherlands)

^e i3 Innovus   (United Kingdom)

^f UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cervical cancer; Cost effectiveness; HPV; The Netherlands

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER PREVENTION; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION PREVENTION; MAJOR CLINICAL STUDY; NETHERLANDS; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; UTERINE CERVIX CANCER; VIRUS INFECTION;

CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MODELS, STATISTICAL; NETHERLANDS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 67650263391     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.085     Document Type: Article

References (77)

1. Ferlay J, Bray P, Pizani P, Parkin DM. Cancer incidence, mortality, and prevalence worldwide. Available at: http://www-depiarcfr.
2. Parkin D.M., and Bray F. The burden of HPV-related cancers. Vaccine 24 August(Suppl 3) (2006) S11-25
3. Boot H.J., Wallenburg I., de Melker H.E., Mangen M.J., Gerritsen A.A., van der Maas N.A., et al. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine 25 August (33) (2007) 6245-6256
4. www.cbs.nl. bevolkingsaantallen.
5. Franco E.L., Rohan T.E., and Villa L.L. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91 March (6) (1999) 506-511
6. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., and El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 6 April (4) (2005) 204
7. Baseman J.G., and Koutsky L.A. The epidemiology of human papillomavirus infections. J Clin Virol 32 March (Suppl 1) (2005) S16-24
8. IARC. IARC monographs on the evaluation of carcinogenic risk to human. Human Papillomaviruses (2005) 90
9. Arbyn M., and Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. J Clin Virol 38 March (3) (2007) 89-97
10. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 Februari (6) (2003) 518-527
11. Stanley M. Prophylactic HPV vaccines. J Clin Pathol 60 September (9) (2007) 961-965
12. Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 August (2) (2004) 278-285
13. Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121 August (3) (2007) 621-632
14. Future, II., study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 May (19) (2007) 1915-1927
15. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 May (19) (2007) 1928-1943
16. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 November (9447) (2004) 1757-1765
17. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 April (9518) (2006) 1247-1255
18. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 June (9580) (2007) 2161-2170
19. Schwarz T.F., and Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 22 (2008)
20. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 December (11) (2006) 1459-1466
21. Ault K.A. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 June (9576) (2007) 1861-1868
22. http://www.cdc.gov/vaccines/recs/acip/downloadings/mtg-slides-feb07/08-hpv-2-barr.pdf
23. Gall S., Teixeira J., Cosette M., Naud P., Harper D., Franco E.L., et al. Substantial impact on precancerious lesions and HPV infections through 5.5 years in women vaccinated with the HPV 16/18 L1 VLP ASO4 cancidate vaccine. AACR annual meeting. Los Angeles, CA (2007)
24. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis Feb 23 (2009)
25. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol Jul 22 (2008)
26. (January 13, 2008). http://www.cvz.nl/resources/cfh0714%20papillomavirusvaccin-Gardasil%20FER_tcm28-23111.pdf
27. www.gr.nl. Rapport vaccinatiestrat 21e eeuw.
28. Hubben G.A., Bos J.M., Glynn D.M., van der Ende A., van Alphen L., and Postma M.J. Enhanced decision support for policy makers using a web interface to health-economic models-illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine 25 May (18) (2007) 3669-3678
29. Welte R., van den Dobbelsteen G., Bos J.M., de Melker H., van Alphen L., Spanjaard L., et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine 23 December (4) (2004) 470-479
30. www.gr.nl. Cervical cancer.
31. Rebolj M., van Ballegooijen M., Berkers L.M., and Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 120 February (4) (2007) 806-812
32. van Ballegooijen M., and Hermens R. Cervical cancer screening in the Netherlands. Eur J Cancer 36 November (17) (2000) 2244-2246
33. Van Ballegooijen M, Rebolj M, Meerding WJ, Van den Akker-van Marle ME, Berkers LM, Habbema JD. The practice of population screening for cervical cancer in the Netherlands in 2001. Report within the framework of the National Evaluation of Population Screening for Cervical Cancer (LEBA) Part 3. ISBN 90-77283-0604; October 2003.
34. Postma M.J., Baltussen R.M., Heijnen M.L., de Berg L.T., and Jager J.C. Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence. Drugs Aging 17 October(3) (2000) 217-227
35. Zwart-van Rijkom J.E., Leufkens H.G., Busschbach J.J., Broekmans A.W., and Rutten F.F. Differences in attitudes, knowledge and use of economic evaluations in decision-making in The Netherlands. The Dutch results from the EUROMET Project. Pharmacoeconomics 18 August (2) (2000) 149-160
36. http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed on January 13, 2008.
37. World Health Organization. Macroeconomics and Health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva, Switzerland; 2001.
38. Ferko N., Postma M.J., Gallivan S., Kruzikas D., and Drummond M. Evolution of the health economics of cervical cancer vaccination. Vaccine S26 (2008) F3-F15
39. Garnett G.P., Kim J.J., French K., and Goldie S.J. Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24 August (Suppl 3) (2006) S178-S186
40. Rogoza R.M., Ferko N., Bentley J., Meijer C.J., Berkhof J., Wang K.L., et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 26 September (Suppl 5) (2008) F46-58
41. Brisson M., Van de Velde N., De Wals P., and Boily M.C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 25 July (29) (2007) 5399-5408
42. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 April (8) (2004) 604-615
43. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 August (6) (2003) 781-789
44. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9 January (1) (2003) 37-48
45. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13 Januari (1) (2007) 28-41
46. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10 November (11) (2004) 1915-1923
47. Dasbach E.J., Elbasha E.H., and Insinga R.P. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 28 (2006) 88-100
48. Thiry N, Lambert M-L, Cleemput I, Huybrechts M, Neyt M, Hulstaert F, et al. Vaccinatie ter Preventie van Baarmoederhalskanker in België: Health Technology Assessment (HTA). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE); 2007. KCE-reports vol. 64A (D2007/10.273/41).
49. Welte R., Postma M., Leidl R., and Kretzschmar M. Costs and effects of chlamydial screening: dynamic versus static modeling. Sex Transm Dis 32 August (8) (2005) 474-483
50. Kohli M., Ferko N., Martin A., Franco E.L., Jenkins D., Gallivan S., et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer 96 January (1) (2007) 143-150
51. National Cancer Registry data; 2006.
52. Bulk S., Van Kemenade F.J., Rozendaal L., and Meijer C.J. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 57 April (4) (2004) 388-393
53. Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 September (9490) (2005) 991-998
54. Jacobs M.V., Walboomers J.M., Snijders P.J., Voorhorst F.J., Verheijen R.H., Fransen-Daalmeijer N., et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 87 July (2) (2000) 221-227
55. www.cbs.nl. sterfte.
56. Berkhof J., de Bruijne M.C., Zielinski G.D., and Meijer C.J. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. Int J Cancer 115 June (2) (2005) 268-275
57. Bos A.B., van Ballegooijen M., van den Akker-van Marle M.E., and Habbema J.D. Less pap-2 results ('minor abnormalities') in the population screening for cervical cancer since the introduction of new guidelines in 1996. Ned Tijdschr Geneeskd 146 August (34) (2002) 1586-1590
58. van den Akker-van Marle M.E., van Ballegooijen M., van Oortmarssen G.J., Boer R., and Habbema J.D. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst 94 February (3) (2002) 193-204
59. Berkers L.M., van Ballegooijen M., van Kemenade F.J., Rebolj M., Essink-Bot M.L., Helmerhorst T.J., et al. The 1996 revision of the Dutch cervical cancer screening programme: increased coverage, fewer repeat smears and less opportunistic screening. Ned Tijdschr Geneeskd 151 June (23) (2007) 1288-1294
60. Van Ballegooijen M, Rebolj M, Meerding WJ, van den Akker-van Marle ME, Berkers LM, Habbema D. De praktijk van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland in 2001. ISBN 90-77283-06-4; 2003.
61. Berkhof J., de Bruijne M.C., Zielinski G.D., Bulkmans N.W., Rozendaal L., Snijders P.J., et al. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 118 April (7) (2006) 1759-1768
62. Coupe V.M., Berkhof J., Verheijen R.H., and Meijer C.J. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. Bjog 114 April (4) (2007) 416-424
63. Meerding W.J., van Ballegooijen M., Burger M.P., van den Akker-van Marle M.E., Quint W.G., and Habbema J.D. Human papillomavirus testing for triage of women referred because of abnormal smears. a decision analysis considering outcomes and costs. J Clin Epidemiol 55 October (10) (2002) 1025-1032
64. Www.cbs.nl. inflatiecijfers.
65. Health Care Insurance Board. Dutch Guidelines for Pharmacoeconomic research (in Dutch). http://wwwcvznl.
66. Wheeler C., Teixeira J., Romanowski B., De Carvalho N.S., Dubin G., and Schuind A. High and sustained HPV-16 and 18 antibody levels through 6.4 years in women vaccinated with Cervarix™ (GSK HPV-16/18 ASO4 vaccine). European society for paediatric infectious diseases (2008)
67. David M.P., Van Herck K., Hardt K., Tibaldi F., Dubin G., Descamps D., et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 11 (2009)
68. Brouwer W., and van Hout B. How should different life expectancies be valued? Diminishing marginal utility and discounting future effects have similar consequences. BMJ 317 October (7166) (1998) 1155
69. Oostenbrink J.B., Bouwmans C.A., Koopmanschap M.A., and Rutten F.F.H. Richtlijnen voor Kostenschattingen in de Gezondheidszorg (Guideline for costing research, methods and standardized prices for economic evaluations in health care) (2004), Health Care Insurance Board, Diemen, Netherlands [in Dutch]
70. Gravelle H., Brouwer W., Niessen L., Postma M., and Rutten F. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ 16 March (3) (2007) 307-317
71. Chesson H.W., Ekwueme D.U., Saraiya M., and Markowitz L.E. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 14 Februari (2) (2008) 244-251
72. Regan D.G., Philp D.J., Hocking J.S., and Law M.G. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex Health 4 September (3) (2007) 147-163
73. Schneider A., Hammerschmidt T., Schwartz T.F., Rogoza R.M., Ferko N., and Siebert U. Langfristige Public-Health-Effekte einer Impfung gegen Zervixkarzinom in Deutschland (Long term public health impact of vaccination against cervical cancer in Germany). Geburtsh Frauenheilk 68 (2007) 850-858
74. Techakehakij W., and Feldman R.D. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine 26 November (49) (2008) 6258-6265
75. Brown DR. HPV Type 6/11/16/18 Vaccine: First Analysis Of Cross-Protection Against Persistent Infection, Cervical Intraepithelial Neoplasia (CIN), And Adenocarcinoma In Situ (AIS) Caused By Oncogenic HPV Types In Addition To 16/18. Intersience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), poster presentation G-1720b, Chicago 17-19th September 2007.
76. Frazer I. Correlating immunity with protection for HPV infection. Int J Infect Dis 11 November (Suppl 2) (2007) S10-S16
77. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16 and 18. Vaccine 24 July (27-28) (2006) 5571